Idiopathic Pulmonary Fibrosis

The prevalence of patients with interstitial lung disease who receive treatment varied across countries, with some sex- and race-based differences, according to results published in CHEST.

HONOLULU — Treatment with nintedanib plus pirfenidone resulted in a similar frequency of adverse events as monotherapy among patients with idiopathic pulmonary fibrosis, according to a systemic review presented at the CHEST Annual Meeting.

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.

The FDA granted orphan drug designation to zelasudil for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

WASHINGTON — In patients with idiopathic pulmonary fibrosis, yearly lung function decline rates did not improve with two different dosages of ziritaxestat, according to an American Thoracic Society International Conference presentation.

Almost 90% of Americans are unaware of the symptoms that signal pulmonary fibrosis due to the disease’s rarity, according to a Pulmonary Fibrosis Foundation survey.

The FDA granted orphan drug designation to INS018_055, an anti-fibrotic small molecule inhibitor, for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Compared with visual assessment, a deep learning model improved CT imaging prediction of histopathologic usual interstitial pneumonitis in patients with interstitial lung disease, according to study results published in CHEST.

The FDA granted orphan drug designation to ifenprodil for the treatment of patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Saracatinib appeared to be “equal or superior” in stopping fibrotic responses compared with two FDA-approved antifibrotic drugs, according to a preclinical study published in American Journal of Respiratory and Critical Care Medicine.